Xconomy’s EXOME Presents: What’s Hot in Boston Biotech

06 April, 2016

After an unprecedented multi-year bull run, biotech is facing headwinds once again. Drug companies have become a target in an election year, putting pricing strategies under a microscope. Valuations have tumbled, drying up a fertile ground for IPOs. Yet biotech innovation continues apace, particularly in Boston. Gene editing has taken the scientific world by storm, and may soon reach human clinical testing. New ways of harnessing the immune system to battle cancer are being unlocked. Investments in neuroscience, long a drug development minefield, have picked up. And local venture firms are armed with new funds to spend on startups.

 
Related News
Xconomy’s EXOME Presents: What’s Hot in Boston Biotech
04.06.16
After an unprecedented multi-year bull run, biotech is facing headwinds once again. Drug companies have become a target in an election year, putting pricing strategies under a microscope. Valuations have tumbled, drying up a fertile ground for IPOs. Yet biotech innovation continues apace, particularly in Boston. Gene editing has taken the scientific world by storm, and may soon reach human clinical testing. New ways of harnessing the immune system to battle cancer are being unlocked. Investments in neuroscience, long a drug development minefield, have picked up. And local venture firms are armed with new funds to spend on startups. Read Full Release
Xconomy Forum: Robo Madness: The A.I. Explosion
03.31.16
Major advances are happening in robotics and the driving force behind it—artificial intelligence. Now companies of all sizes are using emerging A.I. technologies from deep learning to computer vision to natural language processing to build their businesses—and impact our daily lives. Think Google, Facebook, iRobot, and a whole new generation of startups: the technologies are already starting to transform retail, advertising, social media, transportation, connected homes, and other industries. Read Full Release